Tags

Type your tag names separated by a space and hit enter

Cidofovir in the therapy and short-term prophylaxis of poxvirus infections.
Trends Pharmacol Sci 2002; 23(10):456-8TP

Abstract

Although it is often stated that only vaccination would be able to contain or protect the population against a catastrophic smallpox outbreak, the acyclic nucleoside phosphonate analog cidofovir offers a valuable alternative for the therapy and short-term pre- and post-exposure prophylaxis, not only of smallpox but also of other poxvirus infections and DNA viruses. Cidofovir has proven effective against vaccinia, cowpox and monkeypox in various animal model infections. In cell culture, cidofovir has demonstrated activity against variola virus, the etiological agent of smallpox, and in patients it has shown marked efficacy against molluscum contagiosum and orf, two poxvirus infections. Cidofovir is available as an aqueous solution for intravenous administration and could be reformulated for topical (cream or gel), intranasal (aerosol) or peroral (as a lipid prodrug) use, should the need arise.

Authors+Show Affiliations

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Erik.DeClercq@rega.kulueven.ac.be

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12368068

Citation

De Clercq, Erik. "Cidofovir in the Therapy and Short-term Prophylaxis of Poxvirus Infections." Trends in Pharmacological Sciences, vol. 23, no. 10, 2002, pp. 456-8.
De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol Sci. 2002;23(10):456-8.
De Clercq, E. (2002). Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends in Pharmacological Sciences, 23(10), pp. 456-8.
De Clercq E. Cidofovir in the Therapy and Short-term Prophylaxis of Poxvirus Infections. Trends Pharmacol Sci. 2002;23(10):456-8. PubMed PMID: 12368068.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. A1 - De Clercq,Erik, PY - 2002/10/9/pubmed PY - 2002/11/26/medline PY - 2002/10/9/entrez SP - 456 EP - 8 JF - Trends in pharmacological sciences JO - Trends Pharmacol. Sci. VL - 23 IS - 10 N2 - Although it is often stated that only vaccination would be able to contain or protect the population against a catastrophic smallpox outbreak, the acyclic nucleoside phosphonate analog cidofovir offers a valuable alternative for the therapy and short-term pre- and post-exposure prophylaxis, not only of smallpox but also of other poxvirus infections and DNA viruses. Cidofovir has proven effective against vaccinia, cowpox and monkeypox in various animal model infections. In cell culture, cidofovir has demonstrated activity against variola virus, the etiological agent of smallpox, and in patients it has shown marked efficacy against molluscum contagiosum and orf, two poxvirus infections. Cidofovir is available as an aqueous solution for intravenous administration and could be reformulated for topical (cream or gel), intranasal (aerosol) or peroral (as a lipid prodrug) use, should the need arise. SN - 0165-6147 UR - https://www.unboundmedicine.com/medline/citation/12368068/Cidofovir_in_the_therapy_and_short_term_prophylaxis_of_poxvirus_infections_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-6147(02)02091-6 DB - PRIME DP - Unbound Medicine ER -